Genetically modified clostridium strains expressing recombinant antigens and uses thereof
OwnerAleksandra KUBIAK, Tom BAILEY +2inventors
InventorsAleksandra KUBIAK, Tom BAILEY, Niall BOLLARD, Philip HITTMEYER
Life of this patent
Estimating the term…
Abstract
The present invention relates to genetically modified Clostridium strains that provide improved combinations of functional features useful for several medical applications requiring the preparation and administration of antigens. In particular, clinical grade spores generated from the Clostridium strains described herein can be efficiently prepared, stored, formulated for oral administration, and advantageously used in the prevention and/or treatment of infectious diseases, such as COVID-19.
Claims27
A genetically modified Clostridium strain expressing at least one recombinant antigen and presenting one or more additional genome modifications for deleting and/or to inactivating at least one Clostridium gene, wherein said strain is modified to inactivate or attenuate:
- a) at least one Clostridium gene encoding a toxic activity;
- and
- b) at least one Clostridium gene encoding a metabolic activity.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for preventing or treating a disease comprising administering a pharmaceutical composition according to claim 26 to a subject in need thereof.
(canceled)
Dependencies are inferred from the claim text.